AVEO granted patents for lab tests to recognize cancer patients more likely to respond to tivozanib AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, announced the issuance of U today.S http://edmdrx.com . Patent Nos. 7,615,353, in November 2009 which issued, and 7,736,861, yesterday which issued. These patents cover two different diagnostic tests for identifying human individuals likely to react to treatment with tivozanib, AVEO’s highly potent and selective inhibitor of VEGF receptors 1, 2 and 3, which has been evaluated in a global Phase 3 medical trial currently, TIVO-1, in sufferers with renal cell cancer .
Researchers at the University of Utah Departments of Neurology and Individual Genetics, in collaboration with experts at Duke University INFIRMARY, have discovered that mutations in the ATP1A3 gene trigger the disease in nearly all patients with a diagnosis of AHC. The study was published on-line on Sunday, 29 July, 2012, in Character Genetics. In a collaborative effort with the AHC Foundation, Kathryn J. Swoboda, M.D., co-first author on the study, associate professor of pediatrics and neurology, and director of the Pediatric Electric motor Disorders Research System at the University of Utah, established an international database of patients with AHC from around the global world, starting with a single family 14 years back nearly.